GLP-1 patients say their medication can feels weaker. Research points to body adaptation, sleep, stress, and hormonal shifts as the usual culprits.
Worried about “Ozempic personality”? The FDA’s 2026 review of 107,910 patients tells a more reassuring story than the headlines do.
A new mouse study suggests pausing a GLP-1 makes restarts less effective. Here is how strong the evidence is and what to think about before a break.
Canada is approving generic Ozempic, India already has. Here is what it means for US prices, when patents expire, and what you can actually do today.
GLP-1 users are buying more hot sauce & ketchup, and the food industry is moving fast. Here is what the science says about taste changes on GLP-1s.
How to vet a peptide provider in 2026: licensed pharmacy, named clinician, honest labeling, plus free tools and red flags to know before you buy.
Starting July 1, 2026, Medicare Part D patients could get GLP-1s for $50/month. Here's who qualifies, what's covered, and what's still in motion.
Lab testing finds many grey-market peptides miss their purity claims, with heavy metals and bacterial contamination in samples. Here is what to know.
Search compounded GLP-1 pharmacy additives by state. Filter 503A or 503B, compare ingredients, and find a telehealth that works with your pharmacy.
Wegovy and Zepbound coverage is dropping for millions. Learn why GLP-1 prices often jump after you start, and what to do when your costs change.
Food noise is the constant background chatter about food some people live with. Here is what it is, what science shows, and why GLP-1s revealed it.
Wondering about GLP-1s? Here are five basics on candidacy, dosing, food noise, and compounded options to know before your first appointment.
